CN113575573A - Preservation solution for sputum sample and application thereof - Google Patents
Preservation solution for sputum sample and application thereof Download PDFInfo
- Publication number
- CN113575573A CN113575573A CN202111043693.9A CN202111043693A CN113575573A CN 113575573 A CN113575573 A CN 113575573A CN 202111043693 A CN202111043693 A CN 202111043693A CN 113575573 A CN113575573 A CN 113575573A
- Authority
- CN
- China
- Prior art keywords
- percent
- preservation solution
- mucus
- preservative
- inorganic salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Sampling And Sample Adjustment (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a preservation solution for a sputum sample and application thereof, wherein the preservation solution comprises the following components: according to the mass percentage, 0.5-3% of mucus digestant, 35-40% of cell fixative, 0.10-0.15% of phosphate, 0.78-0.85% of inorganic salt, 0-0.05% of preservative and the balance of water; wherein the mucus digestant is at least one of dithiothreitol, N-acetylcysteine, L-cysteine, S- (carboxymethyl) -L-cysteine, trypsin, ammonium thioglycolate, sodium thioglycolate and sodium 2-mercaptoethanesulfonate; the cell fixing agent is three or more than three of methanol, ethanol, isopropanol, glycol or glycerol. The preservation solution disclosed by the invention can maintain the stability of the sputum sample and can also rapidly liquefy the sputum, so that the liquefied sputum sample can be directly used for cytological detection.
Description
Technical Field
The invention relates to the technical field of biological detection, and particularly relates to a preservation solution for a sputum sample and application thereof.
Background
The phlegm is sticky in nature and can be classified into phlegm of mucus, purulent phlegm, foam phlegm and blood-silk phlegm according to its nature. Almost every type of sputum contains mucus which, when used directly in smears, envelops cellular components, making the cell density in the field of view small, leading to difficulties in reading the smear. Meanwhile, a large number of exfoliated cells in the sputum are dispersed in the mucus, and the cells are easily deformed or damaged, so that the detection positive rate is low. The sputum cell preservation time is short, and if fresh sputum sample can not be fixed in 1 hour, the cell easily takes place autolysis or long fungus phenomenon, influences the result and explains.
Sputum tests, including microscopic examination, smear examination, and pathogenic microorganism examination, can aid in the diagnosis or confirmation of certain respiratory diseases. The sputum examination mainly determines whether pathogenic microorganisms exist in sputum of a patient through examination of a sputum smear, so that the sputum sample is possibly polluted for too long time to cause inaccurate examination results, and the sputum sample cannot be stored in a refrigerator even if being stored in the refrigerator, and various bacteria also exist in the refrigerator.
Disclosure of Invention
Therefore, the invention provides a preservation solution for a sputum sample and application thereof.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides a preservation solution for a sputum sample, which comprises the following components: according to the mass percentage, 0.5-3% of mucus digestant, 35-40% of cell fixative, 0.10-0.15% of phosphate, 0.78-0.85% of inorganic salt, 0-0.05% of preservative and the balance of water;
wherein the mucus digestant is at least one of dithiothreitol, N-acetylcysteine, L-cysteine, S- (carboxymethyl) -L-cysteine, trypsin, ammonium thioglycolate, sodium thioglycolate and sodium 2-mercaptoethanesulfonate;
the cell fixing agent is three or more than three of methanol, ethanol, isopropanol, glycol or glycerol;
the inorganic salt is two or more of sodium chloride, sodium acetate, sodium bicarbonate, sodium sulfate or disodium ethylene diamine tetraacetate.
Preferably, the preservation solution consists of: according to the mass percentage, the mucus digestant comprises 1.25 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is dithiothreitol;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
Preferably, the preservation solution consists of: according to the mass percentage, 0.5 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is S- (carboxymethyl) -L-cysteine;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
Preferably, the preservation solution consists of: according to the mass percentage, 1.5 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is N-acetylcysteine;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
Preferably, the preservation solution consists of: according to the mass percentage, 0.8 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is N-acetylcysteine;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
Preferably, the preservation solution consists of: according to the mass percentage, the mucus digestant comprises 3 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is ammonium thioglycolate;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
Preferably, the pH value of the preservation solution is 6.80-7.20.
The invention also provides application of the preservation solution for the sputum sample in preservation of a biological sample.
Preferably, the biological sample is a sputum sample.
The invention has the following advantages:
the sputum preservation solution can reduce the surface tension of thick sputum to reduce the viscosity of the sputum, can hydrolyze macromolecular protein into products such as polypeptide and amino acid, and simultaneously protect sputum cells from being damaged and release the effective components of the sputum cells. Greatly improves the sampling quality and the detection positive rate, reduces the sputum viscosity, is easy for smear, thin-layer liquid-based and microscopic observation, and improves the preservation time of sputum cells. After the sputum sample is treated by the preservation solution, viscous mucus of the sputum sample can be liquefied into a watery state, and filamentous sputum of blood can effectively remove red blood cells, so that the cells are released from blood filaments, and the positive rate can be obviously improved. The sputum treated by the preservation solution is smear or thin-layer fluid-based, the background of the slide is clean, mucus and blood sample fragments do not exist, cells are uniformly distributed, sufficient cell components are contained, the slide is easy to read, and observation and diagnosis are convenient. The sputum sample can be preserved for a long time in the preservation solution, cells are not degenerated, and the sputum sample can be normally sliced and stained after being placed for 7-10 days.
The preservation solution disclosed by the invention can maintain the stability of the sputum sample and can also rapidly liquefy the sputum, so that the liquefied sputum sample can be directly used for cytological detection.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It should be apparent that the drawings in the following description are merely exemplary, and that other embodiments can be derived from the drawings provided by those of ordinary skill in the art without inventive effort.
The structures, ratios, sizes, and the like shown in the present specification are only used for matching with the contents disclosed in the specification, so as to be understood and read by those skilled in the art, and are not used to limit the conditions that the present invention can be implemented, so that the present invention has no technical significance, and any structural modifications, changes in the ratio relationship, or adjustments of the sizes, without affecting the effects and the achievable by the present invention, should still fall within the range that the technical contents disclosed in the present invention can cover.
FIG. 1 is a specimen No. A1 slide staining pattern of the preservation solution treatment of example 1 of the present invention;
FIG. 2 is a staining chart of specimen No. B1 slide processed from the preservation solution of example 1 of the present invention;
FIG. 3 is a staining chart of specimen No. C1 slide processed from the preservation solution of example 1 according to the present invention;
FIG. 4 is a specimen No. A2 slide staining pattern of the preservation solution treatment of example 2 of the present invention;
FIG. 5 is a specimen No. B2 slide staining pattern of the preservation solution treatment of example 2 of the present invention;
FIG. 6 is a staining chart of specimen No. C2 slide processed from the preservation solution of example 2 according to the present invention;
FIG. 7 is a photograph showing the staining of a specimen No. A3 slide treated with the preservation solution of example 3 according to the present invention;
FIG. 8 is a specimen No. B3 slide staining pattern of the preservation solution treatment of example 3 of the present invention;
FIG. 9 is a staining chart of specimen No. C3 slide processed from the preservation solution of example 3 of the present invention;
FIG. 10 is a photograph showing the staining of a specimen No. A4 slide treated with the preservation solution of example 4 according to the present invention;
FIG. 11 is a staining chart of specimen No. B4 slide processed by the preservation solution of example 4 of the present invention;
FIG. 12 is a staining chart of specimen No. C4 slide prepared by treating the preservation solution of example 4 according to the present invention;
FIG. 13 is a photograph showing the staining of a specimen No. A5 slide treated with the preservation solution of example 5 of the present invention;
FIG. 14 is a staining chart of specimen No. B5 slide processed by the preservation solution of example 5 of the present invention;
FIG. 15 is a staining chart of specimen No. C5 slide processed from the preservation solution of example 5 of the present invention;
FIG. 16 is a photograph showing the staining of a specimen No. A6 slide treated with the preservation solution of example 6 according to the present invention;
FIG. 17 is a specimen No. B6 slide staining pattern of the preservation solution treatment of example 6 according to the present invention;
FIG. 18 is a staining chart of specimen No. C6 slide processed from the preservation solution of example 6 according to the present invention;
FIG. 19 is a photograph showing the staining of a specimen No. A7 slide treated with the preservation solution of example 7 according to the present invention;
FIG. 20 is a specimen No. B7 slide staining pattern of the preservation solution treatment of example 7 according to the present invention;
FIG. 21 is a staining chart of specimen No. C7 slide processed from the preservation solution of example 7 according to the present invention;
FIG. 22 is a photograph showing staining of a specimen No. D1 slide treated with the preservation solution of comparative example 1 according to the present invention;
FIG. 23 is a photograph showing staining of a specimen No. D2 slide treated with the preservation solution of comparative example 1 according to the present invention;
FIG. 24 is a staining chart of specimen No. D3 slide treated with the storage solution of comparative example 1 according to the present invention.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The embodiment provides a sputum sample preservation solution, which mainly comprises a mucus digestant, a cell fixing agent, a buffer solution, inorganic salt and a preservative. Wherein the mucus digestant is at least one of dithiothreitol, N-acetylcysteine, L-cysteine, S- (carboxymethyl) -L-cysteine, trypsin, ammonium thioglycolate, sodium thioglycolate, and sodium 2-mercaptoethanesulfonate; wherein, the cell fixing agent mainly comprises at least three or more of methanol, ethanol, isopropanol, glycol and glycerol, and the mass concentration percentage for fixing the cells is between 30 and 50 percent; the buffer solution comprises PBS buffer solution, Tris buffer solution, borate buffer solution and carbonate buffer solution. The acid-base buffer system plays an important role in maintaining the cell morphology in the sample. The pH value of the sputum sample preservation solution is 6.80-7.20; the inorganic salt is used for adjusting inorganic ion concentration and osmotic pressure, and comprises at least two of sodium chloride, sodium acetate, sodium bicarbonate, sodium sulfate or disodium ethylene diamine tetraacetate, and the balance between the inside and outside of the cell follows the osmotic principle (i.e. the isotonic law) and the charge neutrality principle (i.e. the total number of anions and cations in the solution inside and outside the cell must maintain the net charge to be zero). The ion concentration of the sputum sample preservation solution is between 100mM and 180 mM; the preservative comprises ProClin 300 and sodium azide, and the mass percentage is between 0.01 and 0.2 percent.
The use method of the preserving fluid comprises the following steps: after obtaining the sputum, adding about 10mL of preservation solution, placing on an oscillator for oscillation liquefaction, and completing the liquefaction of the sputum within 1min so as to release cells in the viscose. Then, the fixative in the preservation solution dehydrates and fixes each cell according to the permeability of polar molecules, and the buffer solution in the preservation solution protects the morphology of the cell by cooperating with inorganic salt. If the sputum contains blood streak, the fixing agent in the preservation solution can not only break red blood cells, but also has stabilizing and protecting effects on hemoglobin, so that the background of the slide cannot have blood fragments to influence slide reading.
Example 1
The embodiment provides a sputum sample preservation solution, and according to the mass percent, this preservation solution's constitution is: 1.25% of dithiothreitol, 0.58% of sodium chloride, 0.12% of dipotassium phosphate, 0.23% of sodium acetate, 15% of isopropanol, 15% of methanol, 7% of glycerol, 3000.03% of ProClin, and purified water in balance, wherein the pH value of the preservation solution is 7.20.
The preparation method of the sample preservation solution of the present example was:
taking dithiothreitol, sodium chloride, dipotassium hydrogen phosphate, sodium acetate, isopropanol, methanol, glycerol and ProClin 300 according to the proportion.
Adding about half volume of purified water into a beaker, adding dipotassium hydrogen phosphate, stirring to dissolve uniformly, adding sodium chloride and sodium acetate, stirring to dissolve uniformly, adding dithiothreitol, continuing to stir for 5min, sequentially adding isopropanol, methanol and glycerol, adding the next material after stirring uniformly when adding one material, finally adding ProClin 300, and supplementing with purified water. After the preparation, the solution was measured with a pH meter and pH adjustment was performed using sodium hydroxide or hydrochloric acid.
Example 2
The embodiment provides a sputum sample preservation solution, and according to the mass percent, this preservation solution's constitution is: 1.5% of N-acetylcysteine, 0.58% of sodium chloride, 0.12% of dipotassium phosphate, 0.23% of sodium acetate, 15% of isopropanol, 15% of methanol, 7% of glycerol, 3000.03% of ProClin and purified water, wherein the pH value of the preservation solution is adjusted by using sodium hydroxide or hydrochloric acid and is 6.80.
The preparation method of the sample preservation solution of the present example was:
taking N-acetylcysteine, sodium chloride, dipotassium hydrogen phosphate, sodium acetate, isopropanol, methanol, glycerol and ProClin 300 according to the proportion;
adding about half volume of purified water into a beaker, then adding dipotassium hydrogen phosphate, stirring and dissolving uniformly, then adding N-acetylcysteine, stirring and dissolving uniformly, then continuing to add sodium chloride and sodium acetate, stirring for 5min, sequentially adding isopropanol, methanol and glycerol, adding the next component after each component is added, stirring uniformly, finally adding ProClin 300, and supplementing with purified water. After the preparation, the solution was measured with a pH meter and pH adjustment was performed using sodium hydroxide or hydrochloric acid.
Example 3
The sputum sample preservation solution provided by the embodiment comprises the following components in percentage by mass: 0.65% of L-cysteine, 0.58% of sodium chloride, 0.12% of dipotassium phosphate, 0.23% of sodium acetate, 15% of isopropanol, 15% of methanol, 7% of glycerol, 3000.03% of ProClin and purified water, wherein the pH value of the solution is 6.80.
The preparation method of the sample preservation solution of the present example was:
taking L-cysteine, sodium chloride, dipotassium hydrogen phosphate, sodium acetate, isopropanol, methanol, glycerol and ProClin 300 according to the proportion.
Adding about half volume of purified water into a beaker, adding dipotassium hydrogen phosphate, stirring to dissolve uniformly, adding L-cysteine, stirring to dissolve uniformly, continuing to add sodium chloride and sodium acetate, stirring for 5min, sequentially adding isopropanol, methanol and glycerol, adding the next component after stirring uniformly when adding one component, finally adding ProClin 300, and supplementing with purified water. After the preparation, the solution was measured with a pH meter and pH adjustment was performed using sodium hydroxide or hydrochloric acid.
Example 4
The embodiment provides a sputum sample preservation solution, according to the mass percent, by the composition of this preservation solution: 0.5% of S- (carboxymethyl) -L-cysteine, 0.58% of sodium chloride, 0.12% of dipotassium phosphate, 0.23% of sodium acetate, 15% of isopropanol, 15% of methanol, 7% of glycerol, 3000.03% of ProClin, and purified water in balance, wherein the pH value of the solution is 7.00.
The preparation method of the sample preservation solution of the present example was:
taking S- (carboxymethyl) -L-cysteine, sodium chloride, dipotassium phosphate, sodium acetate, isopropanol, methanol, glycerol and ProClin 300 according to the proportion;
adding about half volume of purified water into a beaker, then adding dipotassium hydrogen phosphate, stirring to dissolve uniformly, then adding S- (carboxymethyl) -L-cysteine, stirring to dissolve uniformly, then continuing to add sodium chloride and sodium acetate, stirring for 5min, sequentially adding isopropanol, methanol and glycerol, adding the next component after each component is added, stirring uniformly, finally adding ProClin 300, and supplementing with purified water. After the preparation, the solution was measured with a pH meter and pH adjustment was performed using sodium hydroxide or hydrochloric acid.
Example 5
The embodiment provides a sputum sample preservation solution, and according to the mass percent, this preservation solution's constitution is: 0.8% of trypsin, 0.58% of sodium chloride, 0.12% of dipotassium phosphate, 0.23% of sodium acetate, 15% of isopropanol, 15% of methanol, 7% of glycerol, 3000.03% of ProClin and purified water in balance, wherein the pH value of the solution is 7.10.
The preparation method of the sample preservation solution of the present example was:
taking trypsin, sodium chloride, dipotassium hydrogen phosphate, sodium acetate, isopropanol, methanol, glycerol and ProClin 300 according to the proportion;
adding about half volume of purified water into a beaker, then adding dipotassium hydrogen phosphate, stirring and dissolving uniformly, then adding sodium chloride and sodium acetate, stirring and dissolving uniformly, then adding trypsin, continuing stirring for 5min, sequentially adding isopropanol, methanol and glycerol, adding the next component after stirring uniformly when adding one component, finally adding ProClin 300, and supplementing with purified water. After the preparation, the solution was measured with a pH meter and pH adjustment was performed using sodium hydroxide or hydrochloric acid.
Example 6
The embodiment provides a sputum sample preservation solution, and according to the mass percent, this preservation solution's constitution is: 3% of ammonium thioglycolate, 0.58% of sodium chloride, 0.12% of dipotassium phosphate, 0.23% of sodium acetate, 15% of isopropanol, 15% of methanol, 7% of glycerol, 3000.03% of ProClin, and the balance of purified water, wherein the pH value of the solution is 7.00.
The preparation method of the sample preservation solution of the present example was:
taking the following components in proportion: ammonium thioglycolate, sodium chloride, dipotassium hydrogen phosphate, sodium acetate, isopropanol, methanol, glycerol and ProClin 300.
Adding about half volume of purified water into a beaker, then adding dipotassium hydrogen phosphate, stirring to dissolve uniformly, then adding ammonium thioglycolate, stirring to dissolve uniformly, then continuing to add sodium chloride and sodium acetate, stirring for 5min, sequentially adding isopropanol, methanol and glycerol, stirring uniformly when adding one component, then adding the next component, finally adding ProClin 300, and supplementing with purified water. After the preparation, the solution was measured with a pH meter and pH adjustment was performed using sodium hydroxide or hydrochloric acid.
Example 7
The embodiment provides a sputum sample preservation solution, and according to mass percent, this preservation solution's constitution is: 1.6 percent of sodium thioglycolate, 0.58 percent of sodium chloride, 0.12 percent of dipotassium phosphate, 0.23 percent of sodium acetate, 15 percent of isopropanol, 15 percent of methanol, 7 percent of glycerol, 3000.03 percent of ProClin and purified water, wherein the pH value of the solution is 7.00.
The preparation method of the sample preservation solution of the present example was:
taking sodium thioglycolate, sodium chloride, dipotassium hydrogen phosphate, sodium acetate, isopropanol, methanol, glycerol and ProClin 300 according to the proportion.
Adding about half volume of purified water into a beaker, then adding dipotassium hydrogen phosphate, stirring and dissolving uniformly, then adding sodium thioglycolate, stirring and dissolving uniformly, then continuing to add sodium chloride and sodium acetate, stirring for 5min, sequentially adding isopropanol, methanol and glycerol, adding the next component after stirring uniformly when adding one component, finally adding ProClin 300, and supplementing with purified water. After the preparation, the solution was measured with a pH meter and pH adjustment was performed using sodium hydroxide or hydrochloric acid.
Test examples
This test example was conducted to examine the effect of the sputum specimen-preserving fluid of the above 7 examples on the treatment of sputum. While comparative example 1 was added as a negative control.
Taking 24 sputum samples, and classifying the sputum samples into thick type and thin type according to the properties of the sputum samples, wherein the thick type is 16 samples, 2 samples are considered in each example preservative fluid and comparative example preservative fluid, the preservative fluid treatment numbers of examples 1-7 are A1-A7, B1-B7, and the comparative example preservative fluid treatment numbers of D1 and D2;
the diluted solution type is 8 cases, the preservation solution of each example and the preservation solution of the comparative example consider that the numbers of 1 case, examples 1 to 7 are C1 to C7, and the number of the comparative example is D3.
Formulation method of comparative example 1: 50mL of purified water was taken, and 0.45g of sodium chloride was added thereto.
According to the sputum sample liquefaction mode: adding the preservation solution of the examples 1-7 and the treatment solution of the comparative example 1 in an amount of 4mL into each sputum sample, shaking and shaking for 5min, standing and fixing for 30min, and observing the liquefaction time of each example. The sputum samples and treatment solutions were added as shown in Table 1
TABLE 1
Each of the examples and comparative examples can completely liquefy the sputum sample, and after the sputum sample is liquefied and fixed, the sputum sample is subjected to slide staining, and the sputum sample is stained by Papanicolaou staining solution, and the microscopic examination results of the staining are shown in FIGS. 1-24.
As can be seen from the slice-making staining images, the number of mucus wiredrawing of the comparative example is large, 2 samples in 3 samples have heavy mucus backgrounds, the slice-making staining images of examples 1 to 7 have cleaner backgrounds, no large mucus wiredrawing exists, the number of mucus in the shape of fragments is small, and the slice-making and diagnosis are not influenced; example 5 had 1 sample with a lighter staining of cells and example 7 had 1 sample with a lower cell density. In view of the combination of cell morphology, density and mucus background, example 6 works best, while the remaining examples work equally well.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (9)
1. The preservation solution for the sputum sample is characterized by comprising the following components: according to the mass percentage, 0.5-3% of mucus digestant, 35-40% of cell fixative, 0.10-0.15% of phosphate, 0.78-0.85% of inorganic salt, 0-0.05% of preservative and the balance of water;
wherein the mucus digestant is at least one of dithiothreitol, N-acetylcysteine, L-cysteine, S- (carboxymethyl) -L-cysteine, trypsin, ammonium thioglycolate, sodium thioglycolate and sodium 2-mercaptoethanesulfonate;
the cell fixing agent is three or more than three of methanol, ethanol, isopropanol, glycol or glycerol;
the inorganic salt is two or more of sodium chloride, sodium acetate, sodium bicarbonate, sodium sulfate or disodium ethylene diamine tetraacetate.
2. The preservation solution for sputum samples according to claim 1,
the preservation solution comprises the following components: according to the mass percentage, the mucus digestant comprises 1.25 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is dithiothreitol;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
3. The preservation solution for sputum samples according to claim 1,
the preservation solution comprises the following components: according to the mass percentage, 0.5 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is S- (carboxymethyl) -L-cysteine;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
4. The preservation solution for sputum samples according to claim 1,
the preservation solution comprises the following components: according to the mass percentage, 1.5 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is N-acetylcysteine;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
5. The preservation solution for sputum samples according to claim 1,
the preservation solution comprises the following components: according to the mass percentage, 0.8 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is N-acetylcysteine;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
6. The preservation solution for sputum samples according to claim 1,
the preservation solution comprises the following components: according to the mass percentage, the mucus digestant comprises 3 percent of mucus digestant, 37 percent of cell fixative, 0.12 percent of dipotassium phosphate, 0.81 percent of inorganic salt, 0.03 percent of preservative and the balance of water;
wherein the mucus digesting agent is ammonium thioglycolate;
the cell fixing agent is 15% of isopropanol, 15% of methanol and 7% of glycerol;
the inorganic salt is 0.58 percent of sodium chloride and 0.23 percent of sodium acetate;
the preservative is ProClin.
7. The preservation solution for sputum samples according to any one of claims 1 to 6,
the pH value of the preservation solution is 6.80-7.20.
8. Use of the preservation solution for sputum samples according to any one of claims 1 to 6 for preserving biological samples.
9. The use according to claim 8,
the biological sample is a sputum sample.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111043693.9A CN113575573A (en) | 2021-09-07 | 2021-09-07 | Preservation solution for sputum sample and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111043693.9A CN113575573A (en) | 2021-09-07 | 2021-09-07 | Preservation solution for sputum sample and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113575573A true CN113575573A (en) | 2021-11-02 |
Family
ID=78241515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111043693.9A Pending CN113575573A (en) | 2021-09-07 | 2021-09-07 | Preservation solution for sputum sample and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113575573A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111238893A (en) * | 2020-01-19 | 2020-06-05 | 湖北泰康医疗设备有限公司 | Method for extracting humoral cells for detecting lung cancer |
| CN114235524A (en) * | 2021-12-10 | 2022-03-25 | 江西业力医疗器械有限公司 | Sputum treatment method |
| CN114403130A (en) * | 2022-01-20 | 2022-04-29 | 灵知蓝诺(北京)生物技术有限公司 | Liquid-based cell preservation solution and preparation method and application thereof |
| CN114480371A (en) * | 2021-12-03 | 2022-05-13 | 辽宁康惠生物科技有限公司 | Method for extracting microbial DNA from sample |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656047A (en) * | 1986-03-06 | 1987-04-07 | Kok Lanbrecht P | Rapid method for cell block preparation |
| CN101974609A (en) * | 2010-09-30 | 2011-02-16 | 贺坚慧 | Pathogenic bacterium liquid-based thin-layer smear detection kit and detection method thereof |
| CN101988875A (en) * | 2010-09-03 | 2011-03-23 | 江苏省原子医学研究所 | Sputum liquid-based treating fluid |
| KR20140090811A (en) * | 2013-01-10 | 2014-07-18 | 전북대학교산학협력단 | Non-gynecologic cell preserving solution |
| CN105409925A (en) * | 2014-09-19 | 2016-03-23 | 孝感宏翔生物医械技术有限公司 | Liquid-based cell preservation solution |
| CN107509722A (en) * | 2017-08-30 | 2017-12-26 | 迈克生物股份有限公司 | Sample preservation liquid |
| CN108770836A (en) * | 2018-08-21 | 2018-11-09 | 生工生物工程（上海）股份有限公司 | Liquid based cell preservative fluid and its preparation method and application |
| CN110742059A (en) * | 2019-11-27 | 2020-02-04 | 武汉医尔特科技有限公司 | Liquid-based cell preservation solution and preparation method thereof |
| CN111020001A (en) * | 2019-12-30 | 2020-04-17 | 申友基因组研究院(南京)有限公司 | Novel saliva preserving fluid and preparation method and application thereof |
-
2021
- 2021-09-07 CN CN202111043693.9A patent/CN113575573A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656047A (en) * | 1986-03-06 | 1987-04-07 | Kok Lanbrecht P | Rapid method for cell block preparation |
| CN101988875A (en) * | 2010-09-03 | 2011-03-23 | 江苏省原子医学研究所 | Sputum liquid-based treating fluid |
| CN101974609A (en) * | 2010-09-30 | 2011-02-16 | 贺坚慧 | Pathogenic bacterium liquid-based thin-layer smear detection kit and detection method thereof |
| KR20140090811A (en) * | 2013-01-10 | 2014-07-18 | 전북대학교산학협력단 | Non-gynecologic cell preserving solution |
| CN105409925A (en) * | 2014-09-19 | 2016-03-23 | 孝感宏翔生物医械技术有限公司 | Liquid-based cell preservation solution |
| CN107509722A (en) * | 2017-08-30 | 2017-12-26 | 迈克生物股份有限公司 | Sample preservation liquid |
| CN108770836A (en) * | 2018-08-21 | 2018-11-09 | 生工生物工程（上海）股份有限公司 | Liquid based cell preservative fluid and its preparation method and application |
| CN110742059A (en) * | 2019-11-27 | 2020-02-04 | 武汉医尔特科技有限公司 | Liquid-based cell preservation solution and preparation method thereof |
| CN111020001A (en) * | 2019-12-30 | 2020-04-17 | 申友基因组研究院(南京)有限公司 | Novel saliva preserving fluid and preparation method and application thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111238893A (en) * | 2020-01-19 | 2020-06-05 | 湖北泰康医疗设备有限公司 | Method for extracting humoral cells for detecting lung cancer |
| CN114480371A (en) * | 2021-12-03 | 2022-05-13 | 辽宁康惠生物科技有限公司 | Method for extracting microbial DNA from sample |
| CN114235524A (en) * | 2021-12-10 | 2022-03-25 | 江西业力医疗器械有限公司 | Sputum treatment method |
| CN114235524B (en) * | 2021-12-10 | 2024-02-23 | 南昌准好生物科技有限公司 | Sputum treatment method |
| CN114403130A (en) * | 2022-01-20 | 2022-04-29 | 灵知蓝诺(北京)生物技术有限公司 | Liquid-based cell preservation solution and preparation method and application thereof |
| CN114403130B (en) * | 2022-01-20 | 2022-12-30 | 灵知蓝诺(北京)生物技术有限公司 | Liquid-based cell preservation solution and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113575573A (en) | Preservation solution for sputum sample and application thereof | |
| Hannah et al. | Liquid paraffin as a rehydrant for air dried buccal smear | |
| CN107509722B (en) | Specimen preservation solution | |
| US8394624B2 (en) | Process for preserving biological materials for extended periods of time | |
| CN110742059A (en) | Liquid-based cell preservation solution and preparation method thereof | |
| Nanninga | Uniqueness and location of the fracture plane in the plasma membrane of Bacillus subtilis | |
| CN113966737A (en) | Cell preservation solution for in vitro analysis and detection and preparation method thereof | |
| Harry et al. | Comparison of physical characteristics and collection and elution performance of clinical swabs | |
| Mukai et al. | Crystalloids in angiomyolipoma: 1. A previously unnoticed phenomenon of renal angiomyolipoma occurring at a high frequency | |
| Kushner et al. | The effect of pH on surface structure and morphology of the extreme halophile, Halobacterium cutirubrum | |
| CN105994252A (en) | Liquid-based thin cell preservation liquid and preparation method thereof | |
| EP1676909A1 (en) | Method of mucus removal and, used therein, cell treatment fluid and storage fluid | |
| CN112741080B (en) | Liquid-based cell preservation treatment liquid and preparation method and application thereof | |
| Dreyer et al. | MORPHOLOGICAL, HISTOCHEMICAL AND X‐RAY MICROANALYTICAL EXAMINATION OF DEPOSITS ON SOFT CONTACT LENSES IN EXTENDED WEARING | |
| KR20140090811A (en) | Non-gynecologic cell preserving solution | |
| KR101395081B1 (en) | Gynecologic cell preserving solution | |
| Buchholz et al. | A simple preparation protocol for shipping and storage of tissue sections for laser ablation-inductively coupled plasma-mass spectrometry imaging | |
| CN116138250B (en) | Puncture cell preservation solution, kit, preservation method and application | |
| CN111972400A (en) | Treatment and preservation reagent for liquid-based cells and microorganisms | |
| Bell Jr et al. | Preparing whole mounts of biological specimens for imaging macromolecular structures by light and electron microscopy | |
| CN113424819A (en) | Non-gynecological cell sample preservation solution and application thereof | |
| CN112710526A (en) | Cell fixing and preserving fluid and preparation method and application thereof | |
| Lickfeld | Chapter IV Transmission Electron Microscopy of Bacteria | |
| Rey et al. | Ultramicrotomy Analysis of Peptide-Treated Cells | |
| CN116649330B (en) | Liquid-based exfoliated cell preservation liquid, kit and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211102 |